1. Home
  2. GBIO vs FEMY Comparison

GBIO vs FEMY Comparison

Compare GBIO & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GBIO
  • FEMY
  • Stock Information
  • Founded
  • GBIO 2016
  • FEMY 2004
  • Country
  • GBIO United States
  • FEMY United States
  • Employees
  • GBIO N/A
  • FEMY N/A
  • Industry
  • GBIO Biotechnology: Pharmaceutical Preparations
  • FEMY Medical/Dental Instruments
  • Sector
  • GBIO Health Care
  • FEMY Health Care
  • Exchange
  • GBIO Nasdaq
  • FEMY Nasdaq
  • Market Cap
  • GBIO 29.2M
  • FEMY 31.9M
  • IPO Year
  • GBIO 2020
  • FEMY 2021
  • Fundamental
  • Price
  • GBIO $0.38
  • FEMY $0.96
  • Analyst Decision
  • GBIO Strong Buy
  • FEMY Strong Buy
  • Analyst Count
  • GBIO 4
  • FEMY 3
  • Target Price
  • GBIO $7.33
  • FEMY $8.67
  • AVG Volume (30 Days)
  • GBIO 1.1M
  • FEMY 362.3K
  • Earning Date
  • GBIO 08-06-2025
  • FEMY 08-07-2025
  • Dividend Yield
  • GBIO N/A
  • FEMY N/A
  • EPS Growth
  • GBIO N/A
  • FEMY N/A
  • EPS
  • GBIO N/A
  • FEMY N/A
  • Revenue
  • GBIO $24,556,000.00
  • FEMY $1,699,232.00
  • Revenue This Year
  • GBIO N/A
  • FEMY $231.84
  • Revenue Next Year
  • GBIO N/A
  • FEMY $245.28
  • P/E Ratio
  • GBIO N/A
  • FEMY N/A
  • Revenue Growth
  • GBIO 146.47
  • FEMY 61.97
  • 52 Week Low
  • GBIO $0.30
  • FEMY $0.69
  • 52 Week High
  • GBIO $3.65
  • FEMY $1.80
  • Technical
  • Relative Strength Index (RSI)
  • GBIO 49.21
  • FEMY 48.09
  • Support Level
  • GBIO $0.32
  • FEMY $0.91
  • Resistance Level
  • GBIO $0.36
  • FEMY $0.95
  • Average True Range (ATR)
  • GBIO 0.03
  • FEMY 0.06
  • MACD
  • GBIO 0.00
  • FEMY 0.01
  • Stochastic Oscillator
  • GBIO 64.67
  • FEMY 31.16

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

About FEMY Femasys Inc.

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

Share on Social Networks: